郑小丽,胡晓波,郑志昌,李明,杨继红,廖尚高
ZHENG Xiaoli,HU Xiaobo,ZHENG Zhichang,LI Ming,YANG Jihong,LIAO Shanggao

• 1:贵州医科大学附属医院药剂科
• 2:贵州医科大学药学院

摘要(Abstract)：

目的 建立复方赤红颗粒中独活、川芎及芍药苷含量的测定方法。方法 分别取复方赤红颗粒、独活阴性样品及独活对照药材各1 g制备独活鉴别的供试品、阴性对照及对照药材溶液，分别取复方赤红颗粒(2 g)、川芎阴性样品(2 g)及川芎对照药材(0.1 g)制备川芎鉴别的供试品、阴性对照及对照药材溶液，采用薄层色谱法(TLC)对独活和川芎进行定性鉴别；取复方赤红颗粒(3 g)制备供试品溶液，采用高效液相色谱(HPLC)法测定芍药苷含量，进行线性关系、精密度、稳定性、重复性和加样回收率试验及上述3批样品的含量测定。结果 独活和川芎的薄层色谱中斑点清晰，阴性无干扰；芍药苷在5.22～167.04 mg/L范围内具有良好线性关系(r=0.999 0),精密度、稳定性及重复性试验的相对标准偏差(RSD)分别为1.14%、1.45%及1.39%;平均加样回收率为102.8%,RSD为1.36%;3批样品芍药苷平均含量分别为1.424 3 mg/g、1.409 1 mg/g及1.432 7 mg/g。结论 复方赤红颗粒的TLC方法专属性高，本研究建立的含量测定方法专属性强、分离度高及重复性好。
Objective To establish a method to determine the contents of heracleum, ligusticum wallichii, and paeoniflorin in compound Chihong granules. Methods One gram of compound Chihong granules, 1 g heracleum-negative sample, 1 g heracleum control medicinal materials were taken to prepare test substance, negative control and control medicinal material solutions for heracleum identification. Two gram of compound Chihong granules, 2 g Ligusticum wallichii-negative sample and 0.1 g ligusticum wallichii control medicinal materials were taken to prepare test substance, negative control and control medicinal material solutions for Ligusticum wallichii identification. Thin layer chromatography(TLC) was applied to qualitatively identify heracleum and Ligusticum wallichii. Three gram of compound Chihong granules were taken to prepare test sample solutions. High performance liquid chromatography(HPLC) was used to determine paeoniflorin content. Linear relationship, precision, stability, repeatability, and sample addition recovery tests were conducted. The contents of the three batches of samples mentioned above were determined. Results The spots in TLC of heracleum and Ligusticum wallichii were clear and negative without interference. Paeoniflorin had a good linear relationship within the range from 5.22 to 167.04 mg/L(r=0.999 0). Relative standard deviation(RSD)of precision, stability, and repeatability tests were 1.14%,1.45%, and 1.39%,respectively. Average sample addition recovery rate was 102.8%, and RSD was 1.36%. Average contents of paeoniflorin in three batches of samples were 1.424 3 mg/g, 1.409 1 mg/g and 1.432 7 mg/g, respectively. Conclusion TLC for compound Chihong granules has high specificity. Content determination established in this experiment has strong specificity, high resolution, and good repeatability.

关键词(KeyWords)： 独活;复方赤红颗粒;薄层色谱鉴别;高效液相;川芎;芍药苷;医院制剂
heracleum;compound chihong granules;thin layer chromatography(TLC);high performance liquid chromatography(HPLC);Ligusticum wallichii;paeoniflorin;hospital preparations

Abstract:

Keywords:

基金项目(Foundation): 白求恩·医学科学研究基金项目(B19263DS)

作者(Author): 郑小丽,胡晓波,郑志昌,李明,杨继红,廖尚高
ZHENG Xiaoli,HU Xiaobo,ZHENG Zhichang,LI Ming,YANG Jihong,LIAO Shanggao

DOI: 10.19367/j.cnki.2096-8388.2023.06.010

参考文献(References)：

• [1] PARISI S,BORTOLUZZI A,SEBASTIANI G D,et al.The Italian society for rheumatology clinical practice guidelines for rheumatoid arthritis[J].Reumatismo,2019,71(S1):22-49.
• [2] JIN S,LI M,FANG Y,et al.Chinese registry of rheumatoid arthritis (CREDIT):Ⅱ.prevalence and risk factors of major comorbidities in chinese patients with rheumatoid arthritis[J].Arthritis Res Ther,2017,19(1):251.
• [3] SPARKS J A.Rheumatoid arthritis[J].Ann Intern Med,2019,170(1):C1-C16.
• [4] GRAVALLESE E M,FIRESTEIN G S.Rheumatoid arthritis-common origins,divergent mechanisms[J].N Engl J Med,2023,388(6):529-542.
• [5] JANG S,KWON E J,LEE J J.Rheumatoid arthritis:pathogenic roles of diverse immune cells[J].Int J Mol Sci,2022,23(2):905.
• [6] SMOLEN J S,LANDEWé R,BIJLSMA J,et al.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs:2019 update[J].Ann Rheum Dis,2020,79(6):685-699.
• [7] 耿研，谢希，王昱，等.类风湿关节炎诊疗规范[J].中华内科杂志，2022(1):51-59.
• [8] RADU A F,BUNGAU S G.Management of rheumatoid arthritis:an overview[J].Cells,2021,10(11):2857.
• [9] MANAN M,SALEEM U,AKASH M,et al.Antiarthritic potential of comprehensively standardized extract of alternanthera bettzickiana:in vitro and in vivo studies[J].ACS Omega,2020,5(31):19478-19496.
• [10]刘永胜.中医治疗风湿痹症的研究进展[J].中国城乡企业卫生，2020,35(12):56-58.
• [11]尹柏坤，左军，李冀.类风湿关节炎的中医药治疗进展[J].中医药信息，2022,39(1):84-88.
• [12]赵磊，万磊，刘健，等.类风湿关节炎骨破坏作用机制及中医药治疗研究进展[J].中国骨质疏松杂志，2021,27(9):1379-1383.
• [13]代琪，叶臻，叶俏波，等.续断来源考证、化学成分及药理作用综述[J].中国药物评价，2020,37(6) :432-436.
• [14]宋献美，单朋涛，张艳燕，等.防风石油醚提取物对TNF-α诱导的类风湿关节炎滑膜细胞增殖、凋亡、cAMP/PKA/CREB通路及AQP1表达的影响[J].中药药理与临床，2023,39(1):44-48.
• [15]聂安政，茹庆国，付智慧.细辛水煎液抗炎镇痛作用研究[J].中医药信息，2021,38(7):40-42.
• [16]梅瑶，徐国波，关焕玉，等.止血精胶囊的制备工艺及质量标准的建立[J].贵州医科大学学报，2021,46(5):540-544.
• [17]王迪磊，钟琳瑛，白洁，等.小儿止哮平喘颗粒质量标准的研究[J].中国新药杂志，2022,31(7):685-692.
• [18]曲别军长，俸明康，张绍山，等.基于多指标成分评价川西高原野生川赤芍的质量[J].中草药，2022,53(18):5842-5850.
• [19]吴玲芳，王子墨，赫柯芊，等.赤芍的化学成分和药理作用研究概况[J].中国实验方剂学杂志，2021,27(18):198-206.
• [20]钟晓辉，曾蔚林，陈春松，等.独活寄生汤对膝骨关节炎患者的疗效、炎症水平及中医证候积分的影响[J].中国当代医药，2022,29(13):122-125.
• [21]曹雯，李崇超.独活的本草考证及常用药对[J].陕西中医药大学学报，2018,41(1) :127-130.
• [22]MA J,MENG Q,ZHAN J,et al.Paeoniflorin suppresses rheumatoid arthritis development via modulating the circ-FAM120A/miR-671-5p/MDM4 axis[J].Inflammation,2021,44(6):2309-2322.
• [23]WANG D D,JIANG M Y,WANG W,et al.Paeoniflorin-6'-O-benzene sulfonate down-regulates CXCR4-Gβγ-PI3K/AKT mediated migration in fibroblast-like synoviocytes of rheumatoid arthritis by inhibiting GRK2 translocation[J].Biochem Biophys Res Commun,2020,526(3):805-812.
• [24]XU H,CAI L,ZHANG L,et al.Paeoniflorin ameliorates collagen-induced arthritis via suppressing nuclear factor-κB signalling pathway in osteoclast differentiation[J].Immunology,2018,154(4):593-603.
• [25]ZHANG L,YU J,WANG C,et al.The effects of total glucosides of paeony (TGP) and paeoniflorin (Pae) on inflammatory-immune responses in rheumatoid arthritis (RA)[J].Funct Plant Biol,2019,46(2):107-117.
• [26]YANG X Z,WEI W.CP-25,a compound derived from paeoniflorin:research advance on its pharmacological actions and mechanisms in the treatment of inflammation and immune diseases[J].Acta Pharmacol Sin,2020,41(11):1387-1394.

文章评论(Comment)：